Skip to main content

Oncology Advances

Featured Content |view more

Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy News

Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy

Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.

Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer Video

Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer

Why test the combination of Trodelvy and pembrolizumab?

Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map News

Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map

Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, ...

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients News

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients

The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber ...

New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma News

New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma

In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at ...

Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer News

Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.